AKT1 and glioblastoma: TREM1 functions as an oncogenic biomarker in TAMs that drives GBM PMT via the TLR4/PI3K/AKT/mTOR axis, with inhibition of TREM1 demonstrating therapeutic potential in both ex vivo and in vivo models.